Paradigm Capital Management Inc. NY Acquires New Holdings in AngioDynamics, Inc. $ANGO

Paradigm Capital Management Inc. NY bought a new stake in AngioDynamics, Inc. (NASDAQ:ANGO) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 671,200 shares of the medical instruments supplier’s stock, valued at approximately $8,732,000. Paradigm Capital Management Inc. NY owned approximately 1.62% of AngioDynamics at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. BlackRock Inc. bought a new position in shares of AngioDynamics in the 2nd quarter valued at $49,480,000. Kotler Kevin bought a new stake in AngioDynamics during the 4th quarter worth $21,997,000. Weber Capital Management LLC ADV bought a new stake in AngioDynamics during the 4th quarter worth $17,978,000. UBS Group AG increased its holdings in AngioDynamics by 83.6% in the 3rd quarter. UBS Group AG now owns 1,102,488 shares of the medical instruments supplier’s stock worth $12,315,000 after purchasing an additional 501,881 shares in the last quarter. Finally, Millennium Management LLC increased its holdings in AngioDynamics by 28.1% in the 3rd quarter. Millennium Management LLC now owns 1,793,152 shares of the medical instruments supplier’s stock worth $20,030,000 after purchasing an additional 393,682 shares in the last quarter. Institutional investors own 89.43% of the company’s stock.

AngioDynamics Price Performance

AngioDynamics stock opened at $15.77 on Tuesday. The stock’s 50 day moving average is $14.03 and its 200 day moving average is $12.10. The firm has a market cap of $651.81 million, a P/E ratio of -18.13 and a beta of 0.33. AngioDynamics, Inc. has a one year low of $9.39 and a one year high of $16.29.

AngioDynamics (NASDAQ:ANGO) last released its earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.04. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. The business had revenue of $86.61 million during the quarter, compared to the consensus estimate of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. Equities analysts anticipate that AngioDynamics, Inc. will post -0.25 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently commented on ANGO shares. Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a research note on Friday, July 17th. Canaccord Genuity Group upped their price objective on AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. HC Wainwright raised their price objective on shares of AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Zacks Research downgraded shares of AngioDynamics from a “hold” rating to a “strong sell” rating in a research report on Thursday, July 16th. Finally, Wall Street Zen raised shares of AngioDynamics from a “hold” rating to a “buy” rating in a report on Saturday. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $19.50.

Insider Activity at AngioDynamics

In other news, SVP Warren Nighan, Jr. sold 23,370 shares of the stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $14.72, for a total transaction of $344,006.40. Following the completion of the sale, the senior vice president directly owned 64,745 shares in the company, valued at $953,046.40. This represents a 26.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 6.00% of the company’s stock.

AngioDynamics Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.